

Copenhagen, Denmark - April 12<sup>th</sup>, 2005

## **Nuevolution A/S and Novo Nordisk A/S sign drug discovery collaboration**

Nuevolution A/S today announced the signing of a drug discovery collaboration in which Nuevolution will use its proprietary Chemetics<sup>®</sup> drug discovery technology to find new drug leads on targets provided by Novo Nordisk.

Knud Aunstrup, CEO of Nuevolution A/S commented "This agreement is an important milestone for Nuevolution. It will validate the use of our Chemetics<sup>®</sup> technology in drug discovery on targets of real interest. I am delighted that Novo Nordisk, one of Europe's leading pharmaceutical companies with a long history of ground-breaking new developments in its area of expertise, has become Nuevolution's first collaboration partner".

### About Nuevolution A/S

Nuevolution is poised to revolutionize the field of drug discovery by utilizing its proprietary Chemetics<sup>®</sup> technology to generate large numbers of potent, structurally diverse, small molecule drug leads to virtually any target in a matter of weeks.

Chemetics<sup>®</sup> represents the ultimate "convergent" drug discovery technology – it is a unique, patent protected hybrid of proven wet chemistry and molecular biology approaches that enables the synthesis of hundreds of millions of chemically diverse drug-like compounds and the accurate selection of target-specific hits in a matter of weeks.

Chemetics<sup>®</sup> allows Nuevolution to rapidly generate unprecedented numbers of potent and (target sub-type) selective drug leads, thus addressing a major current bottleneck in drug discovery and development.

Nuevolution seeks to leverage its broadly applicable Chemetics<sup>®</sup> drug discovery engine through drug discovery partnerships with leading pharmaceutical and biotechnology companies.

Nuevolution A/S employs some 30 world class scientists and business professionals, including 14 Ph.D. qualified individuals. The company was founded in May 2001 and is headquartered in Copenhagen, Denmark.

To date, Nuevolution has raised \$ 27 million in venture capital financing based on the ongoing development of its proprietary Chemetics<sup>®</sup> technology. Investors in Nuevolution include Novo A/S, Nordic Biotech K/S, Scandinavian Life Science Venture, SEB Företagsinvest and Vaekstfonden.

For more information about Nuevolution A/S, please visit the company's website [www.nuevolution.com](http://www.nuevolution.com).

# # #

### **Contacts:**

Knud Aunstrup  
Chief Executive Officer  
Tel: +45 39 13 09 44  
Mobile: +45 27 25 14 44  
Email: [ka@nuevolution.com](mailto:ka@nuevolution.com)

Mark Payne  
Chief Financial Officer  
Tel: +45 39 13 09 47  
Mobile: +45 27 25 14 20  
Email: [mp@nuevolution.com](mailto:mp@nuevolution.com)